Ignite Creation Date:
2024-05-06 @ 8:15 PM
Last Modification Date:
2024-10-26 @ 3:23 PM
Study NCT ID:
NCT06305702
Status:
COMPLETED
Last Update Posted:
2024-03-12
First Post:
2024-03-05
Brief Title:
Real-world Study of Inetetamab in HER2-positive Metastatic Breast Cancer
Sponsor:
Liaoning Tumor Hospital Institute
Organization:
Liaoning Tumor Hospital Institute
Study Overview
Official Title:
Multicenter Real-world Clinical Study of Inetetamab-based Therapy in HER2-positive Metastatic Breast Cancer
Status:
COMPLETED
Status Verified Date:
2024-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
A multicenter real-world study was conducted to gather clinicopathological data from patients with HER2-positive metastatic breast cancer who were treated with inetetamab between 2022 and 2023 The study aimed to estimate the progression-free survival PFS objective response rate ORR disease control rate DCR and adverse events AEs associated with inetetamab therapy
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None